Related Experiment Videos
[Pseudomonas immunoglobulin prophylaxis in patients with burn injuries]
Abstract:
Pseudomonas aeruginosa belongs to the most frequent pathogens isolated from patients with burns. In a mouse model for artificial burns it was found that prophylactic administration of a hyperimmune globulin with antibody titres against P. aeruginosa (Fisher immunotypes 1, 2, 4 and 6) reduced mortality. Therefore, the prophylactic administration of Pseudomonas immunoglobulin was examined in a prospective randomized study in two groups of 13 patients each. Severely burned patients with at least second degree burns over 30% to 70% of the total body surface area received 250 mg Pseudomonas immunoglobulin/kg body weight by the intravenous route between days 3 and 13. After treatment, plasma IgG levels were significantly raised between days 7 and 16 as compared to the controls, yet the incidence of infections caused by P. aeruginosa was not reduced. However, only two of the six infected patients, developed septicaemia, whereas in the control group, local Pseudomonas infection led to septicaemia in five out of seven patients. The number of septicaemic Staphylococcus aureus infections was also lower in patients on immunoglobulin prophylaxis, with two cases compared to four cases in the control group. Due to the limited number of cases studied, statistically significant results could not be obtained, however, there was a positive trend in favour of Pseudomonas immunoglobulin treatment.
Insights
Pseudomonas immunoglobulin prophylaxis in burn patients did not reduce P. aeruginosa infections but showed a trend toward lower mortality from sepsis. This suggests a potential benefit in managing severe burn wound complications.
Area of Science:
- Infectious Diseases
- Immunology
- Burn Medicine
Background:
- Pseudomonas aeruginosa is a common pathogen in burn patients.
- Mouse models suggest hyperimmune globulin against P. aeruginosa reduces mortality.
- Burn patients are susceptible to severe bacterial infections.
Purpose of the Study:
- To evaluate the prophylactic effect of Pseudomonas immunoglobulin in severely burned patients.
- To assess the impact on P. aeruginosa infection rates and associated mortality.
- To analyze changes in plasma IgG levels post-treatment.
Main Methods:
- Prospective randomized study with two groups (13 patients each).
- Intravenous administration of 250 mg/kg Pseudomonas immunoglobulin.
- Treatment administered between days 3 and 13 post-burn.
- Monitoring of infection incidence, sepsis development, and plasma IgG levels.
Main Results:
- Plasma IgG levels significantly increased in the treatment group (days 7-16).
- No significant reduction in P. aeruginosa infection incidence was observed.
- Lower rates of P. aeruginosa-related sepsis in the immunoglobulin group (2/6 vs. 5/7).
- Fewer Staphylococcus aureus sepsis cases in the treatment group (2 vs. 4).
Conclusions:
- Pseudomonas immunoglobulin prophylaxis did not significantly decrease P. aeruginosa infection rates.
- A positive trend suggests reduced mortality from sepsis in burn patients.
- Further studies with larger cohorts are needed to confirm efficacy.